1. Slaughter JR, Slaughter KA, Nichols D, et al. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2001;13:187-96.
2. Starksein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson’s disease. J Nerv Ment Dis 1990;178:27-31.
3. Schrag A, Jahanshahi M, Quinn P. What contributes to depression in Parkinson’s disease? Psychological Medicine 2001;31:65-73.
4. Poewe W, Luginger E. Depression in Parkinson’s disease: impediments to recognition and treatment options. Neurology 2001;52(7):S002-S006.
5. Okun MS, Watts RL. Depression associated with Parkinson’s disease: clinical features and treatment. Neurology 2002;58:1(suppl):S63-S70.
6. Cole SA, Woodard JL, Juncos JL. Depression and disability in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1996;8(1):20-5.
7. Aarsland D, Larsen JP, et al. Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999;14(10):866-74.
8. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson’s disease. J Neural Transm 2000;107(1):59-71.
9. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of PD. Mov Disord 2001;16(3):507-10.
10. Walsh K, Bennett G. Parkinson’s disease and anxiety. Postgrad Med J 2001;77(904):89-93.
11. Richard IH, Schiffe RB, Kurler R. Anxiety and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1996;8(4):383-92.
12. Menza MA. Psychiatric aspects of Parkinson’s disease. Psychiatric Ann 2002;32:99-104.
13. Richard IH, Justus AW, Kurlan R. Relationship between mood and motor fluctuations in PD. J Neuropsychiatry Clin Neurosci 2001;13(1):35-41.
14. Ashburn A, Stack E, Pickering CM, Ward CD. A community-dwelling sample of people with Parkinson’s disease: characteristics of fallers and non-fallers. Age Ageing 2001;30(1):47-52.
15. Wolters EC, Berendse HW. Management of psychosis in Parkinson’s disease. Curr Opin Neurol 2001;14(4):499-504.
16. Juncos JL. Management of psychotic aspects of Parkinson’s disease. J Clin Psychiatry 1999;60:8(suppl):42-53.
17. Wolters EC. Dopaminomimetic psychosis in Parkinson’s disease patients. Neurology 1999;52:7(suppl):S010-S013.
18. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced Parkinson’s disease. Mov Disord 2000;15(2):201-11.
19. Dell’Agnello G, Ceravolo R, et al. SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001;24(4):221-27.
20. Dreisig H, Beckmann J, Wermuth L, et al. Psychological effects of structured cognitive psychotherapy in young patients with Parkinson’s disease (abstr). Nordic J Psychiatry 1999;53(3):217-21.
21. Ludwig CL, Weinberger DR, Bruno G, et al. Buspirone, Parkinson’s disease and the locus ceruleus. Clin Neuropharmacol 1986;9(4):373-8.
22. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16(1):23-45.
23. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease 2001: treatment guidelines. Neurology 2001;56:5(suppl):S1-S88.
24. Ellgring JH. Depression, psychosis, dementia: impact on the family. Neurology 1999;52:7(suppl 3):S17-S20.
